Epidermal growth factor receptor inhibitor-induced papulopustular eruption successfully treated with low-dose oral dapsone

Australas J Dermatol. 2018 Aug;59(3):e219-e220. doi: 10.1111/ajd.12728. Epub 2017 Sep 27.

Authors

Cathy Y Zhao^{1

2}, Rose C Liu^{1

2}, Germana Consuegra^{1

2}, Rina Hui^{2

3}, Pablo Fernandez-Penas^{1

2}

Affiliations

¹ Department of Dermatology, Westmead Hospital, Sydney, New South Wales, Australia.
² Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia.
³ Department of Oncology, Westmead Hospital, Sydney, New South Wales, Australia.

PMID: 28952146
DOI: 10.1111/ajd.12728

No abstract available

Publication types

Letter

MeSH terms

Administration, Oral
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Dapsone / administration & dosage*
Dose-Response Relationship, Drug
Drug Eruptions / drug therapy*
Drug Eruptions / etiology*
Drug Eruptions / physiopathology
Erlotinib Hydrochloride / adverse effects*
Erlotinib Hydrochloride / therapeutic use
Facial Dermatoses / chemically induced
Facial Dermatoses / drug therapy
Facial Dermatoses / physiopathology
Female
Follow-Up Studies
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Middle Aged
Scalp Dermatoses / chemically induced
Scalp Dermatoses / drug therapy
Scalp Dermatoses / physiopathology
Treatment Outcome

Substances

Dapsone
Erlotinib Hydrochloride